New horizons for host defense peptides and lantibiotics

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 545-550

  Dawson, Michael John ^a   Scott, Richard W ^b  

^a Novacta Biosystems Limited   (United Kingdom)

^b PolyMedix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B NY 266; GRAMICIDIN S; HB 1345; HEXAPEPTIDE; HLF 1 11; HOST DEFENSE PEPTIDE; ISEGANAN; LANTIBIOTIC; LINEZOLID; LIPOHEXAPEPTIDE; MICROBISPORICIN; MU 1140; MUTACIN; MW 520; NAI 107; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; NISIN; NON PEPTIDE MIMETIC MOLECULE; NZ 2114; OLIGOMER; OLIGOMERS OF ACETYLATED LYSINE; OMIGANAN; PEPTIDE; PEPTIDOMIMETIC AGENT; PEXIGANAN; PMX 30063; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; TRUNCATED PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ACNE; ACUTE BACTERIA SKIN AND SKIN STRUCTURE INFECTION; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BURN INFECTION; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; DIABETIC FOOT; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; MYCOSIS; NONHUMAN; ORAL MUCOSITIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIOCINS; HUMANS; IMMUNITY, INNATE; INFECTION;

EID: 84867330679     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.006     Document Type: Review

References (59)

1. M. Zasloff Antimicrobial peptides of multicellular organisms Nature 415 2002 389 395
2. K.A. Brogden Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria Nat. Rev. Microbiol. 3 2005 238 250
3. L. Yang, V.D. Gordon, A. Mishra, A. Som, K.R. Purdy, M.A. Davis, G.N. Tew, and G.C.L. Wong Synthetic antimicrobial oligomers induce a composition-dependent topological transition in membranes J. Am. Chem. Soc. 129 2007 12141 12147
4. N. Mookherjee, and R.E.W. Hancock Cationic host defense peptides: innate immune regulatory peptides as a novel approach for treating infections Cell. Mol. Life Sci. 64 2007 922 933
5. D. Yang, A. Biragyn, L.W. Kwak, and J.J. Oppenheim Mammalian defensins in immunity: more than just microbicidal Trends Immunol. 23 2002 291 296
6. F. Niyonsaba, H. Ushio, N. Nakano, W. Ng, K. Sayama, K. Hashimoto, I. Nagaoka, K. Okumura, and H. Ogawa Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines J. Invest. Dermatol. 127 2007 594 604
7. M.J. Nell, G.S. Tjabringa, A.R. Wafelman, R. Verrijk, P.S. Hiemstra, J.W. Drijfhout, and J.J. Grote Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application Peptides 27 2006 649 660
8. Y. Lai, and R.L. Gallo AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense Trends Immunol. 30 2009 131 141
9. Y. Lai, A.E. Villaruz, M. Li, D.J. Cha, D.E. Sturdevant, and M. Otto The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci Mol. Microbiol. 63 2007 497 506
10. M. Li, D.J. Cha, Y. Lai, A.E. Villaruz, D.E. Sturdevant, and M. Otto The antimicrobial peptide-sensing system aps of Staphylococcus aureus Mol. Microbiol. 66 2007 1136 1147
11. S.M. Richards, K.L. Strandberg, and J.S. Gunn Salmonella-regulated lipopolysaccharide modifications Subcell. Biochem. 53 2010 101 122
12. M. Gersemann, J. Wehkamp, and E.F. Stange Innate immune dysfunction in inflammatory bowel disease J. Intern. Med. 2012 10.1111/j.1365-2796.2012.02515.x
13. H. Giamarellou, and G. Poulakou Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69 2009 1879 1901
14. A. Braunstein, N. Papo, and Y. Shai In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria Antimicrob. Agents Chemother. 48 2004 3127 3129
15. D. Liu, and W.F. DeGrado De novo design, synthesis, and characterization of antimicrobial beta-peptides J. Am. Chem. Soc. 123 2001 7553 7559
16. M.D. Boersma, H.S. Haase, K.J. Peterson-Kaufman, E.F. Lee, O.B. Clarke, P.M. Colman, B.J. Smith, W.S. Horne, W.D. Fairlie, and S.H. Gellman Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain J. Am. Chem. Soc. 134 2012 315 323
17. M. Wetzler, and A.E. Barron Progress in the de novo design of structured peptoid protein mimics Biopolymers 96 2011 556 560
18. A.T. Yeung, S.L. Gellatly, and R.E. Hancock Multifunctional cationic host defence peptides and their clinical applications Cell. Mol. Life Sci. 68 2011 2161 2176
19. S. Scheicher, L. Zhang, S. Harris, and T.J. Falla Lipohexapeptide HB1345: a novel anti-infective for acne American Academy of Dermatology Meeting Chicago, IL 2008
20. Y.Q. Xiong, W.A. Hady, A. Deslandes, A. Rey, L. Fraisse, H.H. Kristensen, M.R. Yeaman, and A.S. Bayer Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus Antimicrob. Agents Chemother. 55 2011 5325 5330
21. D. Andes, W. Craig, L.A. Nielsen, and H.H. Kristensen In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model Antimicrob. Agents Chemother. 53 2009 3003 3009
22. H. Sarig, L. Livne, V. Held-Kuznetsov, F. Zaknoon, A. Ivankin, D. Gidalevitz, and A. Mor A miniature mimic of host defense peptides with systemic antibacterial efficacy FASEB J. 24 2010 1904 1913
23. H. Sarig, Y. Goldfeder, S. Rotem, and A. Mor Mechanisms mediating bactericidal properties and conditions that enhance the potency of a broad-spectrum oligo-acyl-lysyl Antimicrob. Agents Chemother. 55 2011 688 695
24. L. Dijkshoorn, C.P. Brouwer, S.J. Bogaards, A. Nemec, P.J. van den Broek, and P.H. Nibbering The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii Antimicrob. Agents Chemother. 48 2004 4919 4921
25. A. Lupetti, C.P. Brouwer, S.J. Bogaards, M.M. Welling, E. de Heer, M. Campa, J.T. van Dissel, R.H. Friesen, and P.H. Nibbering Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection J. Infect. Dis. 196 2007 1416 1424
26. A.M. van der Does, S.J. Bogaards, L. Jonk, M. Wulferink, M.P. Velders, and P.H. Nibbering The human lactoferrin-derived peptide hLF1-11 primes monocytes for an enhanced TLR-mediated immune response Biometals 23 2010 493 505
27. A.M. van der Does, S.J. Bogaards, B. Ravensbergen, H. Beekhuizen, J.T. van Dissel, and P.H. Nibbering Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colony-stimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens Antimicrob. Agents Chemother. 54 2010 811 816
28. W.J. Velden, T.M. van Iersel, N.M. Blijlevens, and J.P. Donnelly Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11) BMC Med. 7 2009 44
29. M.G. Scott, E. Dullaghan, N. Mookherjee, N. Glavas, M. Waldbrook, A. Thompson, A. Wang, K. Lee, S. Doria, and P. Hamill An anti-infective peptide that selectively modulates the innate immune response Nat. Biotechnol. 25 2007 465 472
30. N. Mookherjee, D.N. Lippert, P. Hamill, R. Falsafi, A. Nijnik, J. Kindrachuk, J. Pistolic, J. Gardy, P. Miri, and M. Naseer Intracellular receptor for human host defense peptide LL-37 in monocytes J. Immunol. 183 2009 2688 2696
31. D. Liu, S. Choi, B. Chen, R.J. Doerksen, D.J. Clements, J.D. Winkler, M.L. Klein, and W.F. DeGrado Nontoxic membrane-active antimicrobial arylamide oligomers Angew. Chem. Int. Ed. Engl. 43 2004 1158 1162
32. G.N. Tew, D. Clements, H. Tang, L. Arnt, and R.W. Scott Antimicrobial activity of an abiotic host defense peptide mimic Biochim. Biophys. Acta 1758 2006 1387 1392
33. A. Violette, S. Fournel, K. Lamour, O. Chaloin, B. Frisch, J.P. Briand, H. Monteil, and G. Guichard Mimicking helical antibacterial peptides with nonpeptidic folding oligomers Chem. Biol. 13 2006 531 538
34. P. Claudon, A. Violette, K. Lamour, M. Decossas, S. Fournel, B. Heurtault, J. Godet, Y. Mély, B. Jamart-Grégoire, M.C. Averlant-Petit, and J.P. Briand Consequences of isostructural main-chain modifications for the design of antimicrobial foldamers: helical mimics of host-defense peptides based on a heterogeneous amide/urea backbone Angew. Chem. Int. Ed. Engl. 49 2010 333 336
35. G.N. Tew, R.W. Scott, M.L. Klein, and W.F. Degrado De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications Acc. Chem. Res. 43 2010 30 39
36. H. Tang, R.J. Doerksen, T.V. Jones, M.L. Klein, and G.N. Tew Biomimetic facially amphiphilic antibacterial oligomers with conformationally stiff backbones Chem. Biol. 13 2006 427 435
37. S. Choi, A. Isaacs, D. Clements, D. Liu, H. Kim, R.W. Scott, J.D. Winkler, and W.F. DeGrado De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers Proc. Natl. Acad. Sci. U. S. A. 106 2009 6968 6973
38. B. Mensa, Y.H. Kim, S. Choi, R. Scott, G.A. Caputo, and W.F. DeGrado Antibacterial mechanism of action of arylamide foldamers Antimicrob. Agents Chemother. 55 2011 5043 5053
39. J. Hua, R.W. Scott, and G. Diamond Activity of antimicrobial peptide mimetics in the oral cavity. II. Activity against periopathogenic biofilms and anti-inflammatory activity Mol. Oral Microbiol. 25 2010 426 432
40. G. Jung Lantibiotics: a survey G. Jung, H.G. Sahl, Nisin and Novel Lantibiotics 1991 Escom 1 34
41. C. Piper, P.D. Cotter, R.P. Ross, and C. Hill Discovery of medically significant lantibiotics Curr. Drug Discov. Technol. 6 2009 1 18
42. J. Yuan, Z.Z. Zhang, X.Z. Chen, Y. Yang, and L.D. Huan Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants Appl. Microbiol. Biotechnol. 64 2004 806 815
43. J.H. Lee, X. Li, and D.J. O'Sullivan Transcription analysis of a lantibiotic gene cluster from Bifidobacterium longum DJO10A Appl. Environ. Microbiol. 77 2011 5879 5887
44. D. Field, C. Hill, P.D. Cotter, and R.P. Ross The dawning of a 'golden era' in lantibiotic bioengineering Mol. Microbiol. 78 2010 1077 1087
45. W. Liu, A.S.H. Chan, H. Liu, S.A. Cochrane, and J.C. Vederas Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147 J. Am. Chem. Soc. 133 2011 14216 14219
46. E.M. Bavin, A.S. Beach, R. Falconer, and R. Friedman Nisin in experimental tuberculosis Lancet 259 1952 127 129
47. B.P. Goldstein, J. Wei, K. Greenberg, and R. Novick Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model J. Antimicrob. Chemother. 42 1998 277 278
48. M. Mota-Meira, H. Morency, and M.C. Lavoie In vivo activity of mutacin B-Ny266 J. Antimicrob. Chemother. 56 2005 869 871
49. O. Ghobrial, H. Derendorf, and J.D. Hillman Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140 Eur. J. Pharm. Sci. 41 2010 658 664
50. O. Ghobrial, H. Derendorf, and J.D. Hillman Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140 J. Pharm. Sci. 99 2010 2521 2528
51. O. Ghobrial, H. Derendorf, and J.D. Hillman Pharmacodynamic activity of the lantibiotic MU1140 Int. J. Antimicrob. Agents 33 2009 70 74
52. S. Sivagnanam, and D. Deleu Red man syndrome Crit. Care Med. 7 2003 119 120
53. D. Jabes, C. Brunati, G. Candiani, S. Riva, G. Romano, and S. Donadio Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens Antimicrob. Agents Chemother. 55 2011 1671 1676
54. S. Chatterjee, D.K. Chatterjee, R.H. Jani, J. Blumbach, and B.N. Ganguli Mersacidin, a new antibiotic from Bacillus. In vitro and invivo antibacterial activity J. Antibiotics 45 1992 839 845
55. A. Malabarba, M. Landi, R. Pallanza, and B. Cavalleri Physico-chemical and biological properties of actagardine and some acid hydrolysis products J. Antibiotics 38 1985 1506 1511
56. A. Malabarba, R. Pallanza, M. Berti, and B. Cavalleri Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine J. Antibiotics 43 1990 1089 1097
57. M.C. Rea, E. Clayton, P.M. O'Connor, F. Shanahan, B. Kiely, R.P. Ross, and C. Hill Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains J. Med. Microbiol. 56 2007 940 946
58. G.E. Gardiner, M.C. Rea, B. O'Riordan, P. O'Connor, S.P. Morgan, P.G. Lawlor, B.P. Lynch, M. Cronin, R.P. Ross, and C. Hill Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract Appl. Environ. Microbiol. 73 2007 7103 7109
59. J. Reunanen, and P.E.J. Saris Survival of nisin activity in intestinal environment Biotechnol. Lett. 31 2009 1229 1232